Results 271 to 280 of about 198,261 (297)

Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Dapsone is a potent antibacterial agent used as a first‐line treatment for leprosy and employed also as an anti‐inflammatory agent. Additionally, dapsone is used for a variety of other cutaneous conditions. Herein, we report a case of intermediate junctional epidermolysis bullosa that improved significantly with oral 4,4’‐diamino‐diphenyl ...
Shiho Mori   +2 more
wiley   +1 more source

Association of Blood Eosinophil Counts with Expiratory Airflow Limitation: A Multi-Ethnicity Observational Study. [PDF]

open access: yesJ Inflamm Res
Xue J   +11 more
europepmc   +1 more source

Editorial: Update on eosinophil-associated diseases. [PDF]

open access: yesFront Allergy
Diny NL, Yamada Y, Zimmermann N.
europepmc   +1 more source

A Refractory Leg Skin Ulcer Associated With Multiple Myeloma Successfully Treated With Plasma Exchange, Lenalidomide, and Dexamethasone

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder that primarily presents with CRAB symptoms (calcium elevation, renal failure, anemia, and bone abnormalities). In rare cases, MM manifests with systemic complications like skin ulcers, which present management challenges. Here, we report a 78‐year‐old Japanese man with MM and refractory
Naoko Hattori   +5 more
wiley   +1 more source

Relationship Between Clozapine-Induced Inflammation and Eosinophilia: A Retrospective Cohort Study. [PDF]

open access: yesSchizophr Bull
Kikuchi Y   +6 more
europepmc   +1 more source

Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths

open access: green, 2019
Quan Li   +7 more
openalex   +1 more source

Eosinophilic Gastroenteritis with Atopic Dermatitis: A Case Report and Literature Review. [PDF]

open access: yesJ Asthma Allergy
Song H   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy